Date:	12/14/2022
Your Name:	Alexander Bystritsky
Manuscript Title:	Pursuing personalized medicine for depression by targeting lateral or medial prefrontal cortex with Deep TMS
Manuscript Number (if known):	165271-INS-CMED-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Y	a verter	Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	, Click the Saly key to add additional rows:
		Time frame: past 36 month	ns - Maria Mar
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠ None	
7	Support for attending meetings and/or travel	⊠  None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
0.02	Other financial or non-financial interests	[⊠] None	

12/18/2012. AD, PAD

Date:	9/11/2022
Your Name:	Hadar Shalev
Manuscript Title:	Pursuing personalized medicine for depression by targeting lateral or medial prefrontal cortex with Deep TMS
Manuscript Number (if known):	165271-INS-CMED-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	9/11/2022
Your Name:	Frederic Deutsch
Manuscript Title:	Pursuing personalized medicine for depression by targeting lateral or medial prefrontal cortex with Deep TMS
Manuscript Number (if known):	165271-INS-CMED-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.		I am the statistician who worked on the analyses of this manuscript. Payments were made to the company I work for: BioStats Statistical Consultant Ltd.  Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None	
		BrainsWay Ltd.	I am the statistician who worked on the analyses of this manuscript. Payments were made to the company I work for: BioStats Statistical Consultant Ltd.
5	Payment or honoraria for lectures, presentations,	None     Non	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	⊠ None	
7 Support for attending   Mone			
	meetings and/or travel		
8	Patents planned, issued or		
	pending		
9 Participation on  None			
	a Data Safety Monitoring Board or	BrainsWay Ltd.	Payments were made to the company I work for: BioStats Statistical Consultant Ltd.
	Advisory Board		
10	Leadership or fiduciary role in	⊠ None	
	other board, society,		
	committee or advocacy group, paid or unpaid		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	9/11/2022
Your Name:	Uri Alyagon
Manuscript Title:	Should lateral or medial prefrontal cortex be targeted by deep transcranial-magnetic-stimulation to treat depression?
Manuscript Number (if known):	165271-JCI-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.		None	Click the tab key to add additional rows.
		Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).		None	
3	Royalties or licenses		None	

			cations/Comments (e.g., if payments were o you or to your institution)
4	Consulting fees	None  I work part time as an EEG consultant for Brainsway	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None   Brainsway	
8	Patents planned, issued or pending	None  filed patent PCT/IL2017/051163 entitled "Apparatus and methods for predicting therapy outcome"	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	9/11/2022
Your Name:	Yiftach Roth
Manuscript Title:	Pursuing personalized medicine for depression by targeting lateral or medial prefrontal cortex with Deep TMS
Manuscript Number (if known):	165271-INS-CMED-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None   BrainsWay	I am a co-inventor of Deep TMS and have financial interest in BrainsWay  Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

□ None  BrainsWay  □ None	I have stocks of BrainsWay	
<b>⊠</b> None		
or None		
Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	9/9/2022
Your Name:	Abraham Zangen
Manuscript Title:	Pursuing personalized medicine for depression by targeting lateral or medial prefrontal cortex with Deep TMS
Manuscript Number (if known):	165271-INS-CMED-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	□ None	Click the tab key to add additional rows.
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	Israel Science Foundation, European Research Council H2020, Israel Inovation Authority, BrainsWay]	To my institute (Ben Gurion University)
3	Royalties or licenses	National Institute of Health]	To me

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None   BrainsWay]	To me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None   BrainsWay]	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None   BrainsWay	To me.
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Please place an "X" next to the following statement to indicate your agreement:			
Plea [⊠]			

Date:	9/11/2022
Your Name:	Ahava Stein
Manuscript Title:	Pursuing personalized medicine for depression by targeting lateral or medial prefrontal cortex with Deep TMS
Manuscript Number (if known):	165271-INS-CMED-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	-	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date	e:		9/11/2022	
Your Name:			Aron Tendler	
Manuscript Title:			Pursuing personalized medicine for depression by targeting lateral or medial prefrontal cortex with Deep TMS	
Mar	nuscript Number (if	known):	165271-INS-CMED-RV-3	
content of your manuscript. "Related" me affected by the content of the manuscript indicate a bias. If you are in doubt about we the author's relationships/activities/interesting.		ript. "Rela of the man re in doubt ps/activition ension, you	nted" means any relation with for-profit or no nuscript. Disclosure represents a commitment about whether to list a relationship/activity es/interests should be defined broadly. For each should declare all relationships with manufo	/interest, it is preferable that you do so.
	em #1 below, report ne for disclosure is th			ithout time limit. For all other items, the time
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	BrainsV	Time frame: Since the initial planning one Vay	Research funding for this clinical trial  Click the tab key to add additional rows.
			Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	Liva No	va	Research Funding for VNS clinical trial for refractory depression
3	Royalties or licenses		one	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None   BrainsWay	Chief Medical Officer, Half-Time position
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None  Clinical TMS Society	Speaker honoraria
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Clinical TMS Society	Insurance Committee, unpaid

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None   BrainsWay	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	Private practice, commercial TMS center	
Plea	se place an "X" nex	t to the following statement to indicate your agreeme	nt:
	I certify that I have	answered every question and have not altered the wo	rding of any of the questions on this form.

Date:	12/14/2022
Your Name:	Click or tap here to enter text. David Feifel
Manuscript Title:	Pursuing personalized medicine for depression by targeting lateral or medial prefrontal cortex with Deep TMS
Manuscript Number (if known):	165271-INS-CMED-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 months	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	Contracted investigator for Compass Pathways, Mindmed, Relmada, Aptynix, Neurolief, Brainsway, Tripp, Atai,	
3	Royalties or licenses	None None □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None  Speaking honoraria for speaking from Clinical TMS Society	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	⊠  None	
8	Patents planned, issued or pending	Patent pending : PSYCHEDELIC DRUG TREATMENT OF NEUROPSYCHIATRIC DISORDERS AND CEREBRAL PALSY	Patent Issued: Oxytocin treatment to improve memory and modify blood glucose
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Board member: "Kadima Brain Initiative" Clinical TMS Society	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea [		to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:	9/11/2022
Your Name:	Daniel M. Blumberger
Manuscript Title:	Should lateral or medial prefrontal cortex be targeted by deep transcranial-magnetic-stimulation to treat depression?
Manuscript Number (if known):	165271-JCI-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		·	, , ,
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Brainsway site PI for this sponsored clinical trial.	No salary, funds direct to my institution.  Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	Canadian Institutes of Health Research National Institute of Mental Health (US) Brain Canada Magventure	In kind equipment support for investigator initiated trials
3	Royalties or licenses	□ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None   Welcony	1 advisory board meeting
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Clinical TMS Society Clinical Standard Committee Member	

			with whom you have this dicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non-financial interests	None		
Plea	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	12/14/2022
Your Name:	Geoffrey Grammer
Manuscript Title:	Pursuing personalized medicine for depression by targeting lateral or medial prefrontal cortex with Deep TMS
Manuscript Number (if known):	165271-INS-CMED-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	✓ None Janssen	Consulting fees to review educational materials related to Spravato
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	✓ None  Janssen Pharmaceuticals	Payment for educational event related to Spravato
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	Greenbrook TMS NeuroHealth	Stock Options	
12	Receipt of equipment, materials, drugs,	None   Brainsway	Device and EEG materials used in this study	
	medical writing, gifts or other services			
13	Other financial or non-financial interests	None		
Plea	Please place an "X" next to the following statement to indicate your agreement:			
[oxtimes]	I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	12/14/2022
Your Name:	IGOR FILIPCIC
Manuscript Title:	Pursuing personalized medicine for depression by targeting lateral or medial prefrontal cortex with Deep TMS
Manuscript Number (if known):	165271-INS-CMED-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Time frame: Since the initial planning  None	g of the work  Click the tab key to add additional rows.
		Time frame: past 36 mont	hs
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non-financial interests	None		
Plea	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	9/11/2022
Your Name:	Noam Barnea-Ygael
Manuscript Title:	Pursuing personalized medicine for depression by targeting lateral or medial prefrontal cortex with Deep TMS
Manuscript Number (if known):	165271-INS-CMED-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	•	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date	e:	<u>-</u>	9/11/2022		_
You	r Name:	_	Samuel Zibman		
Mar	nuscript Title:	_	Pursuing personalized medicine for depress with Deep TMS	ion by targeting lateral or medial prefrontal cortex	_
Mar	nuscript Number (if kn	nown):	165271-INS-CMED-RV-3		_
cont affe	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.				
epic		sion, you		example, if your manuscript pertains to the acturers of antihypertensive medication, even if	
	em #1 below, report a ne for disclosure is the			ithout time limit. For all other items, the time	
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			· · · · · · · · · · · · · · · · · · ·	made to you or to your institution)	
1	All support for the		hip or indicate none (add rows as needed)  Time frame: Since the initial planning	made to you or to your institution)	
1	r	relationsh	hip or indicate none (add rows as needed)  Time frame: Since the initial planning	made to you or to your institution)	
	All support for the present manuscript (e.g., funding, provision	relationsh	nip or indicate none (add rows as needed)  Time frame: Since the initial planning ne	made to you or to your institution) of the work	
	All support for the present manuscript (e.g.,	relationsh	nip or indicate none (add rows as needed)  Time frame: Since the initial planning ne	made to you or to your institution)	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing	relationsh	nip or indicate none (add rows as needed)  Time frame: Since the initial planning ne	made to you or to your institution) of the work	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	relationsh	nip or indicate none (add rows as needed)  Time frame: Since the initial planning ne	made to you or to your institution) of the work	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	relationsh	nip or indicate none (add rows as needed)  Time frame: Since the initial planning ne	made to you or to your institution) of the work	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for	relationsh	nip or indicate none (add rows as needed)  Time frame: Since the initial planning ne	made to you or to your institution)  of the work  Click the tab key to add additional rows.	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	relationsh	Time frame: Since the initial planning ne ee of BrainsWay  Time frame: past 36 month	made to you or to your institution)  of the work  Click the tab key to add additional rows.	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	relations l	Time frame: Since the initial planning ne ee of BrainsWay  Time frame: past 36 month	made to you or to your institution)  of the work  Click the tab key to add additional rows.	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	relations l	Time frame: Since the initial planning ne ee of BrainsWay  Time frame: past 36 month	made to you or to your institution)  of the work  Click the tab key to add additional rows.	

□ None

Royalties or licenses

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	□ None	
7	Support for attending meetings and/or travel	□ None	
8	Patents planned, issued or pending	□ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	□ None	
13	Other financial or non-financial interests	None	
r 1	-	to the following statement to indicate your agreeme	
	I certify that I have	answered every question and have not altered the wo	rding of any of the questions on this form.

Date:	9/11/2022
Your Name:	Tatiana Gulevsky
Manuscript Title:	Pursuing personalized medicine for depression by targeting lateral or medial prefrontal cortex with Deep TMS
Manuscript Number (if known):	165271-INS-CMED-RV-3

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as nee	Specifications/Comments (e.g., if payments were ded) made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Time frame: Since the initial pla	Click the tab key to add additional rows.
		Time frame: past 36 r	nonths
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	•	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

	ICMJE DISCLOSURE FORM	
Date:	12/14/2022	
Your Name:	12/14/2022 Click or tap here to enter text. Tauya Vapnik  Pursuing personalized medicine for depression by targeting lateral or medial	
Manuscript Title:	Pursuing personalized medicine for depression by targeting lateral or medial prefrontal cortex with Deep TMS	
Manuscript Number known):	r (if 165271-INS-CMED-RV-3	
In the interest of tran related to the content parties whose interes to transparency and	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.	
pertains to the epide	nships/activities/interests should be defined broadly. For example, if your manuscript miology of hypertension, you should declare all relationships with manufacturers of dication, even if that medication is not mentioned in the manuscript.	
	port all support for the work reported in this manuscript without time limit. For all other e for disclosure is the past 36 months.	
	Name all entities with whom you have this Specifications/Comments (e.g., if relationship or indicate none (add rows as payments were made to you or to your needed)	
	Time frame: Since the initial planning of the work	
the present manuscript (e.g., funding, provision of study materials, medical writing, article	■ None  Class the Class of account adoptional to see	
processing charges, etc.) No time limit for this item.		
	Time frame: past 36 months	
2 Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3 Royalties or licenses	⊠ None	
4 Consulting fees	⊠ None	

5 Payment or honoraria for

lectures, presentations,

⊠ None

speakers bureaus, manuscript writing or educational events	
6 Payment for expert testimony	⊠ None
7 Support for attending meetings and/or	⊠ None
travel	
8 Patents planned, issued or pending	⊠ None
9 Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None
11 Stock or stock options	⊠ None
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services	
13 Other financial or non-financial interests	⊠ None
	"next to the following statement to indicate your agreement:

I certify that I hav form. n.

Jacks Vapatie 12/15/22

12/13/2021 ICMUE Disclosure Form

Date:	9/9/2022			
Your Name:	Mark S. George, MD			
Manuscript Title:	Pursuing personalized medicine for depression by targeting lateral or medial prefrontal cortex with Deep TMS			
Manuscript Number (if known):	165271-INS-CMED-RV-3			
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be				

affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	None  I was an enrolling clinical site and money went to MUSC to pay for the conduct of the trial. I was an uncompensated co-leader of the study.  Time frame: past 36 months  None  LivaNova, Neurolief, The George Institute]	Click the tab key to add additional rows.		
3	Royalties or licenses	Books – APPI, Woltar, Elsevier; Journal Editing, Elsevier]			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	Sooma, Neurolief]	Payments to me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	■ None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	Babystrong – taVNS for oromotor feeding, MAAVINS - closed loop taVNS for rehab]	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Several]	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

ľ		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Magstim – Clinical TMS system integrated with EEG]	
13	Other financial or non-financial interests	None	
Please place an "X" next to the following statement to indicate your agreement:			
	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

# The Journal of Clinical Investigation

Click on boxes to check/uncheck items.

# Checklist for submitting a revised Clinical Medicine manuscript

In addition to addressing the items noted in the decision letter regarding your manuscript, ensure that your revised manuscript adheres to the guidelines below. For full submission details, visit the ICI website.

#### Required files

#### Manuscript

PDF of a clean version of the entire manuscript; include references, figures, figure legends, and tables. PDF of a marked-up version of the entire manuscript showing revisions and beginning with a point-by-point response to reviewer comments.

Word or RTF file of all manuscript text; include references, figure legends, tables, and table legends (but not figures, images, markup, or point-by-point responses).

Single PDF file of completed ICMIE uniform disclosure forms from all authors.

For clinical trials, a PDF of the appropriate reporting checklist (CONSORT, STROBE. etc.).

Publication-quality figures in TIFF format. See detailed instructions for figure preparation. Recommended: Graphical abstract (details available here).

#### Supplemental material

Supplemental information, figures, and modest-sized tables, as:

- (a) (if applicable) a PDF in which reviewer-requested changes are highlighted
- (b) a clean, publication-quality PDF

Upload any supplemental videos and/or large spreadsheets separately.

Before submission, carefully review all supplemental files; they will not be checked by a copy editor. The Journal is not responsible for any errors contained in supplemental material.

#### **Blot/gel images**

For any figure showing a cropped blot or gel: a PDF, PPT, or PPTX file (distinct from any other supplemental material) that shows the unedited blot or gel images in their entirety.

Annotate each image as, e.g., "Full unedited gel for Figure 2B."

Clearly indicate which bands were used for the figures.

View Journal policy on gel/blot images.

#### Formatting and style

Recommended 9,000/maximum 12,000 words (including title page, full text, references, figure legends,

Double-spaced throughout, including references and tables; figure legends may be single spaced if necessary to keep a figure and its legend on the same page.

All pages are numbered.

Each section begins on a new page.

#### Abbreviations and acronyms

Standard JCI abbreviations and acronyms are used without definition.

All other abbreviations and acronyms are spelled out at first use in the Abstract and again at first use in the main text (with the abbreviated form appearing in parentheses) and used without definition thereafter.

#### Gene names and symbols

Gene names and symbols conform to official NCBI Gene Nomenclature.

Presented according to JCI Gene nomenclature and style.

Generally reserved for gene symbols, genotypes, and species names.

Terms such as in vivo, in vitro, etc., are not italicized.

#### Unpublished data, manuscripts in preparation or under review, and personal communications

Cited parenthetically in the text, not as numbered references; e.g., "(Jane L. Doe, UCLA, Los Angeles, California, USA, unpublished observations)."

Written permission to cite unpublished observations by individuals external to the author's research team (email is sufficient) is submitted.

#### Reference citations

Appear in parentheses preceded by a space, e.g., "as described previously (1, 2)"; "several research groups (4-10) have found."

No superscript, boldface, italics, etc.

#### Figure and table callouts

Figures and tables are called out in numerical order.

"Figure," "Table," "Supplemental Figure," "Supplemental Table," etc., are spelled out. Callouts appear in parentheses (no boldface or italics) preceded by a space, unless grammatically part of the sentence: "the levels increased (Figure 5A)"; "data shown in Table 2." Parts are called out as, e.g., "Figure 1A," "Figure 2, A and B," "Figure 3, B-D."

## Manuscript preparation and required reporting

#### Title page

#### Manuscript title

Clear, concise, and limited to 15 words, including conjunctions.

Refers to the relevant disease or disease model studied.

No subtitles, colons, periods, or nonstandard abbreviations.

#### **Authors and affiliations**

Author names are provided in full (for example, "Benita J. Sjögren") and in the appropriate order. No titles, honorifics, degrees, or certifications.

Affiliations correspond to the period when the work was performed.

For authors whose affiliation has changed since completion of the work, specify the present affiliation and location below the numbered list.

Affiliation footnotes are assigned consecutively using superscripted numbers (1, 2, 3, etc.).

Affiliations include departments, institutions, city, state (if applicable), and country (but not mailing addresses or zip/regional codes).

Corresponding author's complete name, address, telephone number (including country code if applicable), and email address.

Consortium/study groups shown as authors (e.g., CARDIoGRAM Consortium)

Unless the members of the group appear as authors, each individual member and their affiliation are listed in the supplemental material, under the heading Supplemental Acknowledgments.

The following sentence appears in Acknowledgments: "See Supplemental Acknowledgments for details on {name of consortium}."

#### **Conflict-of-interest statement**

A statement consistent with the Journal's conflict-of-interest policy is included; if no author has a conflict, state the following: "The authors have declared that no conflict of interest exists." If patents are involved, the patent or patent application number(s) are provided and the names of the associated authors specified.

#### Abstract

<u>Structured format</u> with the sections Background, Methods, Results, Conclusion, Trial registration, Funding.

Maximum 250 words.

No references.

All nonstandard abbreviations are defined at first use.

#### Main text (presented in the following order)

#### Introduction

#### Results

#### Discussion

#### Methods

Demographic reporting (see details here)

incomplete, an explanation is provided.

Reporting on race and ethnicity adheres to NIH guidelines or other applicable authoritative standards.

Descriptors for any demographic identities are clear, unbiased, and up-to-date.

Data for any demographic variable are inclusive; if any information is unavailable or

Specify whether the participants or investigators made the classifications; and whether the options were defined by the investigators or participants.

Complete manufacturer name (omit location) is provided for each proprietary item used. For animal models, precise genotype, strain, number of backcrosses, sex, age, and source are specified.

Antibodies: Commercial — source and catalog/clone number are specified for each; custom — generation of antibodies is described (or an appropriate reference is cited).

Source of all cell lines used is indicated.

Data sets for gene expression microarrays, SNP arrays, and high-throughput sequencing studies are deposited in a public repository, and accession number(s) provided in Methods in the main text (for publication, data must be publicly available).

#### Statistics

Section appears near the end of Methods (before "Study approval").

The *P* value used to determine significance of differences is specified; e.g., "A *P* value less than 0.05 was considered significant."

Analysis appropriately corrects for multiple comparisons (more than 2 groups) and for repeated measures (multiple measurements within subjects).

If samples were excluded, a statement describes inclusion/exclusion criteria.

#### Study approval

Stand-alone paragraph at the end of Methods.

Declaration of approval of human and/or animal studies, specifying the official name and location of the applicable institutional review board(s).

For human studies, a statement indicates receipt of written informed consent from participants and/or their parents/guardians.

For use of photographs of participants, a separate statement of written informed consent is included.

#### **Author contributions**

Contribution of each author (identified by initials) is specified; e.g., designing research studies, conducting experiments, acquiring data, analyzing data, providing reagents, writing the manuscript. Multiple contributions may be listed for a single individual, and more than one individual may be associated with a single contribution.

Grammatically complete sentences are used.

For manuscripts with 2 or more co-first authors, the method used to assign authorship order among these authors is stated.

#### Acknowledgments

States sources of support in the form of grants, equipment, or drugs.

Grant numbers are provided as applicable.

Other acknowledgments, such as of colleagues for advice, are included as appropriate.

#### References

Prepared according to How to prepare references for submission.

#### Figure legends

Maximum 300 words.

Each begins with a stand-alone title, irrespective of the individual parts.

Figure parts are called out in boldface: (A), (B-D), (C and E).

Symbols and abbreviations introduced in figures are defined and used consistently throughout. Use of terms within the legends is consistent with that in the figures themselves.

In each figure legend where appropriate, the statistical test(s) used are described.

For each panel representing multiple experiments, the exact number of samples (n) is reported. For representative experiments, the number of times the experiment was conducted is reported.

Error bars are defined either in Statistics or in the individual legends; e.g., "Data represent mean ± SEM."

Variance around the mean and statistical analysis are not provided for figures representing fewer than 3 independent samples.

For histological panels and insets, scale bars are defined or total original magnification is specified in the legends.

#### **Figures**

Prepared according to How to prepare figures for submission.

For clinical trials, the appropriate flow diagram appears as a figure.

Parts are labeled with capital letters: A, B, C, etc., with no designated subparts.

Graphs of quantitative data are presented as either dot plots, with average and appropriate error bars indicated; or box-and-whisker plots, with values defined in the legend (bounds of the boxes, lines within the boxes, whiskers, and any outlying values). Dynamite plunger plots are not permitted.

If lanes in a gel or blot image are spliced together into a composite image, the lanes are distinguished with a thin vertical dividing line (black on a gray background; or white on a black background). State in the legend that the lanes were run on the same gel but were noncontiguous.

#### **Tables**

Prepared in Word table format (not pasted in from another application).

 ${\bf Self\text{-}contained\ and\ self\text{-}explanatory}.$ 

Preceded by brief titles.

Each table fits on a single page and is presented on its own page.

Callouts to footnotes (designated with superscript capital letters) are assigned alphabetically row by row.

No subparts or subsections (for example, Table 1A and Table 1B).

Column headings in tables apply to all values throughout the column; a new row of column headings may not be introduced within a table.

See "Methods" above for reporting on demographics.